Meanwhile, combination of the STAT3 inhibitor and anti-PD-1 antibody synergistically improved T cells activation, CCL5 and IFN-γ releasing in the TME as compared toanti-PD-1 alone, and decreased tumor-infiltrating Tregs, therefore inhibiting the breast cancer progression and metastasis [145]. Here, IFNG is linked to breast carcinoma.